Develops and sells treatments for rare diseases, including medicines for children and patients with metabolic and hormone disorders.
10-K for FY2025, filed Mar 19, 2026
Customers pay for the company's medicines when product is delivered to wholesalers or when stock is shipped to fulfill patient orders. Licensing income can also come from rights deals and development milestones; sales-based royalties are tied to the licensee's product sales.
10-K for FY2025, filed Mar 19, 2026The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or…View ↗
The Company stores its INCRELEX®, ALKINDI SPRINKLE®, KHINDIVITM, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone.…View ↗
Licensing revenue during the twelve-months ended December 31, 2025 was $3.3 million, compared to $0.5 million in licensing revenue during…View ↗
Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the…View ↗
10-K for FY2025, filed Mar 19, 2026
FY2025 revenue by product or service ↗$80M
10-K for FY2025, filed Mar 19, 2026
$80M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License
|
4.1%
FY2022: 47%
|
License, FY2025
$3.3M Sources
|
|
|
Product Sales and Royalties
Sold outright
10-K for FY2025, filed Mar 19, 2026 |
96%
FY2022: 53%
|
Product Sales and Royalties, FY2025
$76.7M Sources
|
Sold outright |
The company sells its medicines to specialty pharmacy and wholesale distributor customers, which handle order fulfillment, storage and distribution; specialty pharmacies then serve patients. The company also earns income from licensing product rights to other companies.
10-K for FY2025, filed Mar 19, 2026The Company operates the business on the basis of a single reportable segment, which includes eight commercial rare disease products…View ↗
The Company sells its INCRELEX®, ALKINDI SPRINKLE®, KHINDIVITM, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone…View ↗
Licensing revenue during the twelve-months ended December 31, 2025 was $3.3 million, compared to $0.5 million in licensing revenue during…View ↗
10-K for FY2025, filed Mar 19, 2026
The Company's revenues and its accounts receivable balances are highly concentrated and consist of sales to and amounts due from AnovoRx…View ↗
Not on paper. It lost $4.6M in FY2025, but brought in more cash than it spent: $10.2M of free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
$35.2MView ↗
8-K, filed Aug 5, 2026
On July 31, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a license agreement (the "Agreement") for a late-stage…View ↗
8-K, filed May 19, 2026
The Company would pay up to an additional $4.0 million by making $1.0 million payments when cumulative net sales reach $50.0 million…View ↗
8-K, filed May 1, 2026
On May 1, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has launched HEMANGEOL® (propranolol)…View ↗
8-K, filed Apr 16, 2026
On April 16, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the appointment of Judith Matthews as…View ↗
Growing. Revenue grew 3.7x in 4 years, from $21.8M in FY2021 to $80M in FY2025, about 38% a year.
Broader commercial product portfolio
The latest report describes eight commercial rare disease products, including several acquired medicines; the older report described three commercial products. The newer report also presents a broader set of late-stage candidates.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 19, 2026The Company currently has three commercial rare disease products, ALKINDI SPRINKLE® for the treatment of adrenocortical insufficiency…View ↗
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. We currently have…View ↗
Fewer out-licensed products described
The older report described royalties or milestone income from several products commercialized by partners. The latest report's product overview centers on the company's own commercial medicines and describes licensing income from rights deals and milestones.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 19, 2026
Loading...